Diamyd Medical secures FDA fast track status for type 1 diabetes treatment

The designation aims to expedite the development and review of the drug for paediatric patients with early-stage Type 1 Diabetes carrying HLA DR3-DQ2 genotype. Credit: Michal Jarmoluk from Pixabay.